CAMBRIDGE, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its investor event at the annual American Society of Hematology (ASH) meeting will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.millennium.com.
The presentation will be delivered by Millennium senior management as well as clinical investigators and will include an overview of clinical trial data for VELCADE(R) (bortezomib) for Injection. The presentation will be delivered at 7:15 p.m. ET on Monday, December 10, 2007 from the Twelve Hotel in Atlanta, Georgia. The presentation will be archived for 30 days.
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has
a robust clinical development pipeline of product candidates. The Company's
research, development and commercialization activities are focused in two
therapeutic areas: oncology and inflammation. By applying its knowledge of
the human genome, understanding of disease mechanisms and industrialized
drug discovery platform, Millennium is developing an exciting pipeline of
innovative product candidates. The Company's website is http://www.millennium.com.
Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com.
|SOURCE Millennium Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved